Autolomous announces the completion of its first round of finance, led by a consortium of US-European investors.

London, UK, June 22nd, 2020 – Autolomous Ltd, a leading-edge developer of innovative digital solutions for the manufacture of advanced medicines, proudly announces today the completion of its first round of fundraising led by a US-European Investor Consortium.

“After a rigorous pursuit of the right long-term partners to further the development of our AutoloMATE platform, we are delighted to make this announcement today. As we begin our partnership, we are confident that the resources and added board-level expertise it brings to our company will be instrumental in driving us to greater success”, said Alexander Seyf, CEO of Autolomous.

“This is an excellent development for Autolomous as we seek to progress our portfolio of offerings and our customer base across Europe and the USA. It allows us to accelerate our development program and the diversity of cell & gene products we can support. Our investors have track records in healthcare and IT investments and share our vision of high quality, cost-effective supply chains for cellular medicines” said Kwok Pang, COO of Autolomous.

Autolomous will be further building its capabilities and capacity to:
● Meet rapidly increasing customer demands in Europe and the USA;
● Expand the functionality of its AutoloMATE platform through developing new products;
● Complete the build of its fully integrated ecosystem.

The AutoloMATE platform will harness leading-edge technologies such as distributed ledger technologies, Internet of Everything and Artificial Intelligence/Machine Learning.